Shijiazhuang Yiling Pharmaceutical Co., Ltd.
002603
Rang in aandelen
#4183
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and... Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.
Aandeelprijs
$2.29
Marktkapitalisatie
$3.83B
Verandering (1 dag)
3.06%
Verandering (1 jaar)
-6.38%
Land
CN
Handel Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603)
Categorie
Healthcare
P/S-ratio voor Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603)
P/S-ratio op October 2026 TTM: 3.19
Volgens de meest recente financiële rapporten en aandelenkoers van Shijiazhuang Yiling Pharmaceutical Co., Ltd. is de huidige P/S-ratio (TTM) 3.19. Eind 2023 had het bedrijf een P/S-ratio van 3.74.
P/S-ratiohistoriek voor Shijiazhuang Yiling Pharmaceutical Co., Ltd. van 2008 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 3.19 | -22.27% |
| 2024 | 4.11 | 9.95% |
| 2023 | 3.74 | -6.47% |
| 2022 | 3.99 | 23.40% |
| 2021 | 3.24 | -6.57% |
| 2020 | 3.46 | 36.02% |
| 2019 | 2.55 | 4.13% |
| 2018 | 2.45 | -42.76% |
| 2017 | 4.27 | -14.66% |
| 2016 | 5.01 | -20.33% |
| 2015 | 6.28 | 13.71% |
| 2014 | 5.53 | -24.41% |
| 2013 | 7.31 | -5.22% |
| 2012 | 7.71 | 1.08% |
| 2011 | 7.63 | -16.06% |
| 2010 | 9.09 | 0.62% |
| 2009 | 9.03 | -42.47% |
| 2008 | 15.71 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.31 | 222.75% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| 15.12 | 373.37% |
US
|
|
| - | - |
IT
|
